Linfomas
GLUN
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (8)
2024
-
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714
2021
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
2013
-
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
Haematologica, Vol. 98, Núm. 10, pp. 1563-1570
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952
2012
2006
-
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol
Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183